Author

Minxian Dai

First Affiliated Hospital of Guangzhou Medical University

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biophysics· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Assay:cryo-EM· 1 Approach:deep learning· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Approach:graph neural network· 1 Research Focus:protein structure prediction· 1 Assay:proteomics· 1

Frequent Co-Authors

Jinsai ShangiD· 2 shared Anqi ZhouiD· 1 shared Bao Xue· 1 shared Guihua Zhang· 1 shared Haizhan JiaoiD· 1 shared Hongli HuiD· 1 shared Hongming CheniD· 1 shared Hua CheniD· 1 shared

Activity by Year

2024-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBiophysics

Jinsai ShangORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Mechanism of fatty acid uptake and inhibition in human FATP2

Zhenglai Zhang, Mengqing Zhou, Y Huang, Wencheng Wu, Haizhan Jiao, Minxian Dai, Taizhen Liang, Jiayue Wen, Ziqi Cheng, Xiancai Ma, Jiao Yuan, Hongli Hu, Jinsai Shang, Ronen Marmorstein, Xuepeng Wei

This paper presents cryo-EM structures of human FATP2, revealing its fatty acid uptake mechanism and drug inhibition strategies.

bioRxiv · Jul 10, 2026 · PreprintBiophysics

Discovery of resistance-resilient quinoline papain-like protease inhibitors through topology-constrained molecular generative design

Yongzhi Lu, Ting Ran, Qi Yang, Guihua Zhang, Jiayi Chen, Peiqi Zhou, Wenqi Li, Minyuan Xu, Jielin Tang, Minxian Dai, Jinpeng Zhong, Hua Chen, Pan He, Anqi Zhou, Bao Xue, , Jinsai Shang

This paper discovers a novel quinoline-based PLpro inhibitor, GZNL-2016, that remains effective against drug-resistant SARS-CoV-2 variants like Omicron BA.5 and XBB.1.

bioRxiv · Sep 7, 2024 · PreprintMicrobiology